Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea

Value in Health

Volumn 15, Issue 1 SUPPL., 2012, Pages

  Yim, Eun Young ^a   Lim, Sang Hee ^a   Oh, Mi Jeong ^a   Park, Hye Kyung ^a   Gong, Ji Ryoun ^a   Park, Sung Eun ^a   Yi, So Young ^a  

^a Health Insurance Review & Assessment Service Korea   (South Korea)

Author keywords

drug reimbursement; Korea; pharmacoeconomic evaluations; quality assessment

Indexed keywords

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG PREFERENCE; ECONOMIC EVALUATION; HUMAN; KOREA; PATIENT COMPLIANCE; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REIMBURSEMENT; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS, PHARMACEUTICAL; FEES, PHARMACEUTICAL; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; REPUBLIC OF KOREA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862946933     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.11.026     Document Type: Conference Paper

References (35)

1. F.M. Clement, A. Harris, J.J. Li Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada JAMA 302 2009 1437 1443
2. K.S. Lee, W.B. Brouwer, S.I. Lee Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? A critical review of published Korean economic evaluations Pharmacoeconomics 23 2005 709 721 (Pubitemid 41003076)
3. B. George, A. Harris, A. Mitchell Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996) Pharmacoeconomics 19 2001 1103 1109 (Pubitemid 33135698)
4. A.H. Harris, S.R. Hill, G. Chin The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 19942004 Med Decis Making 5 2008 713 722
5. M.J. Buxton Economic evaluation and decision making in the UK Pharmacoeconomics 24 2006 1133 1142 (Pubitemid 44683369)
6. M. Tierney, B. Manns Members of the Canadian Expert Drug Advisory Committee Optimizing the use of prescription drugs in Canada through the Common Drug Review CMAJ 178 2008 432 435 (Pubitemid 351303287)
7. Organization for Economic Co-Operation and Development OECD health data 2006: how does Korea compare www.oecd.org/dataoecd/30/40/36959256.pdf [Accessed November 30, 2010]
8. Organization for Economic Co-Operation and Development OECD health data 2010 http://www.oecd.org/document/16/0,3343,en-2649-34631-2085200-1-1-1-1,00. html [Accessed May 24, 2011]
9. Organization for Economic Co-Operation and Development Pharmaceutical pricing and reimbursement policies in Switzerland OECD health working papers No. 27 2007 http://www.oecd.org/dataoecd/54/42/38868953.pdf [Accessed November 30, 2010]
10. Organization for Economic Co-Operation and Development Pharmaceutical pricing and reimbursement policies in Canada OECD health working papers No. 24. 2007 http://www.oecd.org/dataoecd/21/40/37868186.pdf [Accessed November 30, 2010]
11. Organization for Economic Co-Operation and Development Pharmaceutical pricing and reimbursement policies in Sweden OECD health working papers No. 28. 2007 http://www.oecd.org/dataoecd/63/17/40699881.pdf [Accessed November 30, 2010]
12. Regulation No. 93 of Evaluation Criteria, Procedures, and Etc for Reimbursement Determinations of Drugs of December 29 (2006).
13. E.Y. Bae Guidelines for economic evaluation of pharmaceuticals in Korea J Prev Med Public Health 41 2008 80 83
14. J.F. Baladi, D. Menon, N. Otten Use of economic evaluation guidelines: 2 years' experience in Canada Health Econ 7 1998 221 227 (Pubitemid 28230289)
15. A.H. Anis, Y. Gagnon Using economic evaluations to make formulary coverage decisions: so much for guidelines Pharmacoeconomics 18 2000 55 62 (Pubitemid 30468868)
16. M.E. Lim, J.M. Bowen, D. O'Reilly Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literature Value Health 13 2010 328 334
17. S.R. Hill, A.S. Mitchell, D.A. Henry Problems with the interpretation of pharmaeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme JAMA 283 2000 2116 2121 (Pubitemid 30241307)
18. P.J. Neumann, P.W. Stone, R.H. Chapman The quality of reporting in published cost-utility analyses, 19761997 Ann Intern Med 132 2000 964 972 (Pubitemid 30397597)
19. T. Jefferson, V. Demicheli, L. Vale Quality of systematic reviews of economic evaluations in health care JAMA 287 2002 2809 2812 (Pubitemid 34591970)
20. J. Oliva, J. Del Llano, J.A. Sacristn Analysis of economic evaluations of health technologies performed in Spain between 1990 and 2000 Gac Sanit 16 2, Suppl. 2002 S2 S11
21. J.J. Ofman, S.D. Sullivan, P.J. Neumann Examining the value and quality of health economic analyses: implications of utilizing the QHES J Manag Care Pharm 9 2003 53 61
22. B.M. Yang, E.Y. Bae, J. Kim Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance Health Aff (Millwood) 27 2008 179 187 (Pubitemid 351198603)
23. E.Y. Bae, E.K. Lee Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea Value Health 12 3, Suppl. 2009 S36 S41
24. J. Ramsberg, S. Odeberg, A. Engstrm Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden: the first year Eur J Health Econ 5 2004 351 356 (Pubitemid 40543189)
25. B.M. Spiegel, L.E. Targownik, F. Kanwal The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal Gastroenterology 127 2004 403 411 (Pubitemid 39091888)
26. Korea National Enterprise for Clinical Trials http://www.konect.or.kr [Accessed November 30, 2010]
27. National Evidence-based Healthcare Collaborating Agency http://www.neca.re.kr [Accessed November 30, 2010]
28. H.G. Eichler, S.X. Kong, W.C. Gerth Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge Value Health 7 2004 518 528 (Pubitemid 39390832)
29. N. Devlin, D. Parkin Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 2004 437 452 (Pubitemid 38660393)
30. A. Laupacis, D. Feeny, A.S. Detsky How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 146 1992 473 481
31. M.D. Rawilns, A.J. Culyer National Institute for Clinical Excellence and its value judgments BMJ 329 2004 224 227 (Pubitemid 39013284)
32. U. Persson, J. Ramsberg Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions Lakartidningen 104 2007 3046 3050
33. C. McCabe, K. Claxton, A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733 744
34. L. Andronis, P. Barton, S. Bryan Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making Health Technol Assess 13 2009 iii, ixxi, 161
35. Statextracts Organization for Economic Co-Operation and Development http://stats.oecd.org/index.aspx?queryid=558 [Accessed June 9, 2011]